Moderna’s first big success was its coronavirus vaccine -- that product brought in $18 billion in revenue at its peak. The biotech recently submitted a flu vaccine candidate to regulators. But Moderna ...

Moderna (NASDAQ: MRNA) is best known for its coronavirus vaccine, a product that generated more than $18 billion in revenue at its peak in 2022 and helped drive the stock higher during the early days ...

Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines company navigated a “challenging regulatory and business environment.” ...

Disclosure: Our goal is to feature products and services that we think you'll find interesting and useful. If you purchase them, Entrepreneur may get a small share of the revenue from the sale from ...

Add Futurism (opens in a new tab) Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Last year, OpenAI ...

Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology ...

Shares of Moderna on Wednesday surged to their highest in more than a year after the pharmaceutical company said it reached a deal to resolve a dispute related to its COVID vaccine. Moderna MRNA said ...

Moderna said it settled patent lawsuits over its blockbuster COVID-19 vaccine for $950 million, with another $1.3 billion payout possible depending on the outcome of a federal appeal. The ...

Moderna MRNA-7.49%decrease; red down pointing triangle will pay $950 million to settle patent litigation by Arbutus Biopharma and Genevant Sciences GmbH. The vaccine maker said Tuesday that, as part ...

Choosing an operating system in 2026 requires more thought than ever. Windows, macOS, Linux, and ChromeOS each offer unique strengths in hardware compatibility, software support, and user experience.

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...